SOX2OT variant 7 contributes to the synergistic interaction between EGCG and Doxorubicin to kill osteosarcoma via autophagy and stemness inhibition
- PMID: 29475441
- PMCID: PMC6389193
- DOI: 10.1186/s13046-018-0689-3
SOX2OT variant 7 contributes to the synergistic interaction between EGCG and Doxorubicin to kill osteosarcoma via autophagy and stemness inhibition
Abstract
Background: Doxorubicin is the preferred chemotherapeuticdrug for osteosarcoma treatment of which clinical efficacy is limited because of its chemo-resistance and cardiac toxicity. It is necessary to develop the combination regimen with complementary molecular mechanisms to reduce the side effects and enhance sensitivity of Doxorubicin. EGCG is a polyphenol in green tea with antitumor bioactivity,which has been found that its combination with certain chemotherapeutic drugs could improve the antitumor efficiency.
Methods: In this study, MTT assay was used to detect the cell growth inhibition The CD133+/CD44+ cells were isolated from U2OS and SaoS2 cell lines using magnetic-activated cell sorting and identified by flow cytometry analysis. qRT-PCR was used for determining the relative mRNA levels of key genes. Immunofluorescence was performed to evaluate the autophagy flux alterations. Self-renewal ability was accessed by sphere-forming assay. Tumorigenicity in nude mice was preformed to evaluate tumorigenicity in vivo.
Results: We found that EGCG targeting LncRNA SOX2OT variant 7 produced synergistic effects with Doxorubicin on osteosarcoma cell growth inhibition. On the one hand, EGCG could reduce the Doxorubicin-induced pro-survival autophagy through decreasing SOX2OT variant 7 to improve the growth inhibition of Doxorubicin. On the other hand, EGCG could partially inactivate Notch3/DLL3 signaling cascade targeting SOX2OT variant 7 to reduce the stemness then abated drug-resistance of osteosarcoma cells.
Conclusions: This study will help to reveal the molecular mechanisms of synergistic effects of EGCG and Doxorubicin on OS chemotherapy and improve the clinical efficacy of chemotherapy as well as provide a basis for developing antitumor drugs targeting osteosarcoma stem cells.
Keywords: Autophagy; Cancer stem cells; Doxorubicin; EGCG; Notch3; Osteosarcoma; SOX2OT.
Conflict of interest statement
Ethics approval and consent to participate
Use of patient tissue samples for all experiments and the performance of animal experiments were approved by the Ethics Committee of the 2nd Xiangya Hospital of Central South University (2017 Ethical review No.S093).
Consent for publication
Not applicable
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figures






Similar articles
-
LncRNA Sox2OT-V7 promotes doxorubicin-induced autophagy and chemoresistance in osteosarcoma via tumor-suppressive miR-142/miR-22.Aging (Albany NY). 2020 Apr 16;12(8):6644-6666. doi: 10.18632/aging.103004. Epub 2020 Apr 16. Aging (Albany NY). 2020. PMID: 32302291 Free PMC article.
-
Long non-coding RNA CTA sensitizes osteosarcoma cells to doxorubicin through inhibition of autophagy.Oncotarget. 2017 May 9;8(19):31465-31477. doi: 10.18632/oncotarget.16356. Oncotarget. 2017. PMID: 28415557 Free PMC article.
-
Autophagy inhibition contributes to the synergistic interaction between EGCG and doxorubicin to kill the hepatoma Hep3B cells.PLoS One. 2014 Jan 21;9(1):e85771. doi: 10.1371/journal.pone.0085771. eCollection 2014. PLoS One. 2014. PMID: 24465696 Free PMC article.
-
Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.Oncotarget. 2016 Dec 13;7(50):83502-83513. doi: 10.18632/oncotarget.13148. Oncotarget. 2016. PMID: 27835872 Free PMC article. Review.
-
The emerging role of lncRNAs in the regulation of osteosarcoma stem cells.Eur Rev Med Pharmacol Sci. 2022 Feb;26(3):966-974. doi: 10.26355/eurrev_202202_28006. Eur Rev Med Pharmacol Sci. 2022. PMID: 35179763 Review.
Cited by
-
Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine.Chin Med. 2019 Nov 6;14:48. doi: 10.1186/s13020-019-0270-9. eCollection 2019. Chin Med. 2019. PMID: 31719837 Free PMC article. Review.
-
Meta analysis of bioactive compounds, miRNA, siRNA and cell death regulators as sensitizers to doxorubicin induced chemoresistance.Apoptosis. 2022 Oct;27(9-10):622-646. doi: 10.1007/s10495-022-01742-z. Epub 2022 Jun 18. Apoptosis. 2022. PMID: 35716277 Review.
-
Synergistic effects of natural compounds and conventional chemotherapeutic agents: recent insights for the development of cancer treatment strategies.Heliyon. 2022 May 24;8(6):e09519. doi: 10.1016/j.heliyon.2022.e09519. eCollection 2022 Jun. Heliyon. 2022. PMID: 35669542 Free PMC article. Review.
-
Research Progress of Plant-Derived Natural Products against Drug-Resistant Cancer.Nutrients. 2024 Mar 11;16(6):797. doi: 10.3390/nu16060797. Nutrients. 2024. PMID: 38542707 Free PMC article. Review.
-
The combination of high glucose and LPS induces autophagy in bovine kidney epithelial cells via the Notch3/mTOR signaling pathway.BMC Vet Res. 2022 Aug 11;18(1):307. doi: 10.1186/s12917-022-03395-1. BMC Vet Res. 2022. PMID: 35953831 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous